You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新天藥業:擬向子公司碩方醫藥增資1000萬元 促進產品研發能力快速提升
格隆匯 02-11 16:33

格隆匯2月11日丨新天藥業(002873.SZ)公佈,公司為進一步落實公司整體戰略規劃,促進公司產品研發能力的快速提升,擬以自有資金向全資子公司上海碩方醫藥科技有限公司(“碩方醫藥”)增資人民幣1000萬元。此次增資完成後,碩方醫藥的註冊資本將變更為人民幣3000萬元,公司仍持有碩方醫藥100%股權。

上海碩方醫藥科技有限公司經營範圍:從事醫藥科技領域內的技術開發、技術轉讓、技術服務、技術諮詢。(依法須經批准的項目,經相關部門批准後方可開展經營活動)

根據公司內部的可行性論證結果,碩方醫藥作為公司的研發平台之一,此次以自有資金對碩方醫藥進行增資,將有利於促進公司產品研發能力的快速提升,加快產品研發進度,為進一步拓展新的產品市場,從而帶動公司整體銷售收入及利潤的進一步提升做準備。

公司此次增資完成後,將滿足碩方醫藥產品研發投入及經營發展的資金需求,促進公司產品研發能力的快速提升,符合公司整體戰略規劃和業務發展需求

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account